Managing Adverse Events and Integrating Amivantamab Plus Lazertinib

Panelists discuss how effective management of adverse events (AEs) supports successful integration of novel EGFR-targeted combinations like amivantamab and lazertinib. They review toxicity profiles across therapies, noting dermatologic and infusion-related reactions as common concerns. Strategies such as early recognition, prophylactic care, and multidisciplinary support are highlighted for minimizing discontinuation rates and maintaining adherence. The discussion emphasizes that proactive AE management enhances tolerability and patient confidence, ensuring long-term therapy success.